Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts assign Personalis a consensus rating of "Moderate Buy" from seven firms (five buys, one hold, one sell) with an average 12‑month target of $11.50, and several brokers recently raised targets to $13 while Weiss Ratings maintained a "sell (D-)."
• The stock trades around $5.04 (50‑day MA $7.14, 200‑day MA $8.32) with a 1‑year range of $3.62–$11.50 and a market cap of about $528M; Personalis beat Q4 EPS and revenue estimates but remains unprofitable (negative net margin ~116.7% and negative ROE).
• About 61.9% of the company is owned by institutional investors, with several funds modestly increasing their positions in recent quarters.

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $11.50.

A number of research analysts have recently issued reports on PSNL shares. Guggenheim raised their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. BTIG Research lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Needham & Company LLC lifted their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, February 27th. Morgan Stanley cut their price objective on shares of Personalis from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Personalis in a research report on Tuesday, April 21st.

Personalis Stock Performance

Personalis stock opened at $5.04 on Thursday. The firm's 50-day moving average is $7.14 and its 200-day moving average is $8.32. Personalis has a 1 year low of $3.62 and a 1 year high of $11.50. The company has a market cap of $527.58 million, a P/E ratio of -5.54 and a beta of 2.20.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The company had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. As a group, sell-side analysts predict that Personalis will post -1.01 earnings per share for the current year.

Institutional Trading of Personalis

Several hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its position in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company's stock valued at $27,000 after purchasing an additional 1,479 shares during the last quarter. Deutsche Bank AG lifted its position in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company's stock valued at $309,000 after purchasing an additional 1,655 shares during the last quarter. Royal Bank of Canada lifted its position in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC lifted its position in Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company's stock valued at $1,872,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Intech Investment Management LLC lifted its position in Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company's stock valued at $162,000 after purchasing an additional 3,851 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors.

About Personalis

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.